TP1032

TP1032 is an investigational cannabinoid-based pharmaceutical candidate developed by Tetra Pharm Technologies for the treatment of insomnia. The drug is designed to target the endocannabinoid system (ECS), specifically the cannabinoid receptors, which play a significant role in regulating the sleep-wake cycle and maintaining sleep architecture. Tetra Pharm Technologies utilizes proprietary drug delivery systems, such as their X-Caps encapsulation technology or sublingual platforms, to enhance the bioavailability and therapeutic window of the active cannabinoids. TP1032 is part of a broader pipeline of ECS-targeting therapies aimed at neurological and psychiatric conditions.